糖尿病肾病患者尿液白细胞介素-6与肿瘤坏死因子-α检测的临床意义

Clinical Significance of Detection of Urinary Interleukin-6 and Tumor Necrosis Factor-α in Patients with Diabetic Nephropathy

目的 研究并分析糖尿病肾病患者尿液白细胞介素-6与肿瘤坏死因子-α检测的临床意义。方法 该次研究共选取2017年1月—2018年1月该院收治的50例糖尿病肾病患者作为实验组研究对象,并选取同时期在该院进行身体体检的50名健康人员作为对照组研究对象,对比两组人员的临床生化指标以及尿液白细胞介素-6、肿瘤坏死因子-α浓度,对比各类观察指标对于糖尿病肾病的差异。结果 实验组尿液白细胞介素-6为(0.73±0.04)pg/μL、肿瘤坏死因子-α为(2.17±1.2)pg/μL、UACR为(109.2±12.8)mg/g,对照组尿液白细胞介素-6为(0.12±0.03)pg/μL、肿瘤坏死因子-α为(0.74±0.05)pg/μL、UACR为(6.5±1.1)mg/g,两组数据进行比较,差异有统计学意义(t=5.316 4,14.753 1,82.364 3, P<0.05)。结论 尿液肿瘤坏死因子-α可直接反映患者病情严重程度,对患者早期诊断治疗有巨大帮助。

Objective To study and analyze the clinical significance of urine interleukin-6 and tumor necrosis factor-α in patients with diabetic nephropathy. Methods A total of 50 patients with diabetic nephropathy admitted to our hospital from January 2017 to January 2018 were selected as subjects in the experimental group. And 50 healthy people who underwent physical examination in our hospital at the same time were selected as the control group. The clinical biochemical parameters of the two groups, the concentrations of urinary interleukin-6, tumor necrosis factor-α, and the differences of various indicators for diabetic nephropathy were compared. Results Urine interleukin-6 was (0.73±0.04) pg/μL, tumor necrosis factor-α was (2.17±1.2) pg/μL, UACR was (109.2±12.8) mg/g of the experimental group. Liquid interleukin-6 was (0.12±0.03) pg/μL, tumor necrosis factor-α was (0.74±0.05) pg/μL, UACR was (6.5±1.1) mg/g of the control group. And there was difference between the two groups, the difference was statistically significant(t=5.316 4, 14.753 1,82.364 3, P<0.05). Conclusion Urine TNF-a can directly reflect the severity of the patient's condition, which is of great help to the early diagnosis and treatment of patients.